Although the number of safe and high quality biosimilars are increasing in high-income countries, their use remains limited. This is due to problems with acceptance by healthcare systems, doctors and patients, in some cases due to myths around the quality of biosimilar drugs compared to their brand-name counterparts.

Regulatory inconsistencies also impede biosimilar use. Regulatory approval pathways in some countries differ to those of the major regulatory regions, which can lead to a lack of trust.

At the 17th Biosimilar Medicines Conference in The Netherlands, WHO Department for the Regulation of Medicines and other Health Technologies (RHT) outlined several key factors that could increase the use of biosimilar drug products, including:

• Collaboration
Collaboration, such as joint assessments and collaborative registration, can help to increase experience and promote reliance, which is especially important for less experienced National Regulatory Authorities (NRAs).

• Communication
Communicating the appropriate information to policymakers, professionals and patients is important to increase acceptance of biosimilars.

• Education
Similarly, evidence-based findings are important to debunk the myths surrounding biosimilars and build trust in them as safe and effective treatment options. In Europe, the European Medicines Agency provides information on biosimilars for healthcare professionals [1] and patients [2], while in the US the Food and Drug Administration has launched a public educational campaign around biosimilars [3].

Through a range of regulatory activities – such as harmonization of pharmacopeia, the global benchmarking tool [4], post-marketing surveillance and prequalification programmes [5], – WHO aims to contribute to these efforts and ultimately increase patient access to biosimilars.

Related articles
WHO releases Q&A on biosimilars evaluation

Key considerations for biosimilars in the US

How can EU policymakers access the potential of biosimilars

References
1. European Medicines Agency. Biosimilars in the EU. Information guide for healthcare professionals [homepage on the Internet]. [cited 2019 May 3]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
2. European Commission. Information for patients: what I need to know about biosimilar medicines [homepage on the Internet]. [cited 2019 May 3]. Available from: https://ec.europa.eu/growth/content/information-patients-what-i-need-know-about-biosimilar-medicines-0_en
3. US Food and Drug Administration. Biosimilars [homepage on the Internet]. [cited 2019 May 3]. Available from: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm
4. GaBI Online - Generics and Biosimilars Initiative. WHO Global Benchmarking Tool Revision VI includes ‘Listed Authorities’ [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 May 3]. Available from: www.gabionline.net/Reports/WHO-Global-Benchmarking-Tool-Revision-VI-includes-Listed-Authorities  
5. GaBI Online - Generics and Biosimilars Initiative. WHO to launch prequalification programme for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2019 May 3]. Available from: www.gabionline.net/Biosimilars/General/WHO-to-launch-prequalification-programme-for-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.